ArticleScientific reports2026

RRM2 as a biomarker and therapeutic target in letrozole resistant estrogen receptor positive breast cancer.

Wan-Yu Hung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.